Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**YH0618** is an orally administered medicinal-and-edible traditional Chinese formula being investigated as supportive care for chemotherapy-induced toxicities, particularly alopecia and dermatologic adverse effects. Published descriptions of the soup preparation identify black soybean, brown rice, black fungus, and Siraitia grosvenorii fruit as its component foods; a granule-study protocol describes a related five-food formulation that includes liquorice. Preclinical studies suggest that YH0618 reduces doxorubicin-associated injury in normal liver and kidney cells through modulation of FOXO4-associated mitochondrial apoptosis signaling and may attenuate doxorubicin-induced alopecia through keratin-associated and TGF-beta/Smad3-pathway effects. It is not an approved anticancer drug and is intended to mitigate treatment toxicity rather than replace chemotherapy. ([jcancer.org](https://www.jcancer.org/v10p3665.htm))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on YH0618.